Market Overview

UPDATE: Tigress Initiates Coverage On Illumina

Related ILMN
40 Biggest Movers From Yesterday
40 Stocks Moving In Tuesday's Mid-Day Session
Healthcare: The 'Week That Was' Was Good (Seeking Alpha)

In a report released Friday, Tigress analyst Philip Van Deusen initiated coverage on Illumina (NASDAQ: ILMN) with a Buy rating.

Analysts at Tigress favor Illumina for reducing costs in its genomic health progress with its genetic testing, diagnosis and individualized treatment. Illumina's development of hardware will strengthen, influencing an increase to barriers to entry. Tigress holds high expectations for Illumina sequencing machines, growing 51 percent year over year and making a majority of the company's revenue.

Latest Ratings for ILMN

Jan 2018William BlairDowngradesOutperformMarket Perform
Jan 2018BTIG ResearchInitiates Coverage OnNeutral
Jan 2018Evercore ISI GroupInitiates Coverage OnOutperform

View More Analyst Ratings for ILMN
View the Latest Analyst Ratings

Posted-In: Philip Van Deusen TigressInitiation Analyst Ratings


Related Articles (ILMN)

View Comments and Join the Discussion!